Home / Categories / Hormonal & reproductive
These are mostly real prescription drugs.
Mostly real approved drugs, which changes the legal question entirely.
7 compounds tracked in this category
Free, no obligation
Every inquiry gets a real answer from a person. If what you're asking about isn't supported by evidence, we'll say so.
In theory, this class is designed to work with the body's own reproductive signalling rather than override it, driving the pulsatile GnRH, LH and FSH cascade that governs gonadal hormone production, or acting on melanocortin receptors for desire. Most of this category is not theory at all: these are approved prescription drugs with established evidence, which changes the question from whether they work to how you legally obtain them.
Unmarked, FDA approved° legal over the counter† under FDA review, not yet permitted* not FDA approved‡ documented safety concern
| Compound | What is known |
|---|---|
| PT-141 (bremelanotide) | Approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Prescription only. |
| hCG | Approved prescription drug. Dispensing without a prescription is a violation independent of any claim made. |
| Triptorelin | Approved prescription GnRH agonist. |
| hMG / menotropins | Approved prescription fertility drug. |
| Oxytocin | Approved prescription drug. |
| Gonadorelin† | Previously approved as LutrePulse. On the Category 1 list. Prescription route only. |
| Kisspeptin-10* | Unapproved. Research use in reproductive endocrinology. |
The science behind this category
Nearly everything here is an FDA-approved prescription drug. hCG, triptorelin, hMG, oxytocin, and PT-141 (approved as Vyleesi) all went through full review. That makes this the strongest-evidenced category on the site after the metabolic incretins, and it also creates a completely different legal exposure.
For unapproved compounds, the violation concerns introducing an unapproved new drug into commerce. For approved prescription drugs, distributing without a prescription is a separate violation that does not depend on any claim being made. Nothing about how a product is labelled or described changes it. This is worth understanding clearly, because it is the trap in this category.
The hypothalamic-pituitary-gonadal axis runs on pulsatile signalling. GnRH released in pulses drives LH and FSH, which drive gonadal hormone production. The pattern carries the information. Continuous stimulation of the same receptors produces downregulation rather than more output, which is why GnRH agonists are used clinically to suppress rather than stimulate. Anyone reasoning about this axis from intuition tends to get the direction wrong.
Bremelanotide is the case worth knowing. It acts on melanocortin receptors rather than the vascular mechanism of the erectile dysfunction drugs, went through full approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women, and is prescription-only. It is frequently sold outside that framework under its research name.
The outlier here, an unapproved research compound used in reproductive endocrinology studies. Kisspeptin sits upstream of GnRH and is genuinely important in reproductive biology, but its use outside research is not supported.
Understanding a category is the first step. Whether any of it applies to you is a question for a licensed physician who knows your history.
See consultations